|
Targeting Protein Translation to Antagonize MYC-driven Neuroblastoma |
Children’s Hospital of Philadelphia |
Cure4Cam Childhood Cancer Foundation |
|
Preclinical Efficacy of Daratumumab in T Cell Acute Lymphoblastic Leukemia |
New York University School of Medicine |
I Care I Cure |
|
Identification and Targeting of Microenvironmental Factors Controlling Pediatric Leukemia |
New York University School of Medicine |
Cure4Cam Childhood Cancer Foundation |
|
Identification and Characterization of Pathways Dysregulated by MMSET E1099K Mutation in Relapsed Pediatric Acute Lymphoblastic Leukemia and Their Role in Drug Resistance |
New York University School of Medicine |
Tap Cancer Out |
|
Identifying Disease Mechanisms and Therapeutic Opportunities in Pediatric Low-grade Gliomas Driven by MYB-QKI Fusions |
Dana-Farber Cancer Institute |
Northwestern Mutual Foundation |
|
Role of N6-Methyladenosine (m6A) mRNA Modification Pathway in Neuroblastoma |
Boston Children’s Hospital |
Love Your Melon |
|
Restoring RUNX1 Levels in FPD/AML |
University of Washington, Seattle |
The RUNX1 Research Program |
|
Characterization of Pre-Leukemia Associated with Familial RUNX1 Mutations |
Stanford University |
The RUNX1 Research Program |
|
Identifying Therapeutic Targets to Prevent Progression of Familial RUNX1 Disorder to AML Using Novel iPSC Models |
Icahn School of Medicine at Mount Sinai |
The RUNX1 Research Program |
|
Pharmacologic Enhancement of Residual Wild Type RUNX1 Protein Activity in FPD/AML |
Boston Children’s Hospital |
The RUNX1 Research Program |
